Immune cell therapy for hepatitis B-related liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new immune cell therapy (SCG101) for people with a certain type of liver cancer linked to hepatitis B. It's designed for those whose cancer has progressed after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of liver cancer called hepatocellular carcinoma (HCC).
- You must have had at least one standard treatment for liver cancer in the past.
- You need to have a specific immune system marker called HLA-A*02 (a blood test will confirm).
- Your liver cancer must be at stage B or C (intermediate or advanced).
- Your liver function must be relatively good, with a Child-Pugh score of 7 or less.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
This trial tests a new treatment called OriC902 for people with advanced liver cancer (HCC) that has not responded to standard therapies. The treatment uses special immune cells designed to target a protein called GPC3 found on cancer cells. The goal is to see if this approach can help shrink tumors or stop them from growing.
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.